Rare diseases
Investigational molecules
Locations
Kiinamyllynkatu 4-8, 20520 Turku, Finland
Varsinais-Suomen hyvinvointialue in Turku, Finland specialises in clinical trials of conditions such as Acute myeloid leukaemia, Multiple sclerosis, Acute lymphocytic leukaemia, Medulloblastoma, and other specialisations. This site conducts important research.
The center is at the forefront of oncology and radiology, focusing on innovative imaging techniques to enhance cancer diagnosis and treatment. The use of USPIO contrast media in assessing pelvic lymph node metastasis in rectal cancer exemplifies its commitment to precision medicine.
By integrating advanced imaging modalities, the center aims to improve the accuracy of cancer staging and treatment planning.
Specializing in genetic disorders, the center conducts pivotal research on Fabry Disease, focusing on alleviating neuropathic and abdominal pain through novel therapeutic agents like venglustat.
Research efforts are directed towards improving quality of life for patients with rare genetic conditions through targeted therapies.
The center is a leader in prostate cancer research, focusing on long-term safety and efficacy of treatments like enzalutamide for patients who have shown clinical benefit in previous studies.
Ongoing studies aim to refine therapeutic strategies and enhance patient outcomes in prostate cancer management.
Focusing on neurology, the center explores treatments for progressive multiple sclerosis, investigating the reduction of smoldering inflammation using advanced imaging techniques and novel drugs like istradefylline.
Research is dedicated to developing effective therapies that target the underlying mechanisms of neurological diseases.
The center is renowned for its work in pediatric oncology, particularly in the diagnosis and treatment of ependymoma and acute myeloid leukemia in children and adolescents.
Efforts are focused on improving survival rates and treatment outcomes through innovative clinical trials and research protocols.
In the field of neonatal neurology, the center investigates brain perfusion and elasticity in newborns using CEUS and elastography, aiming to understand the impact of various treatments on brain health.
Research is geared towards enhancing diagnostic capabilities and therapeutic interventions for neonatal brain conditions.
Clinical trials currently enrolling participants at this site.
A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes
FinlandA Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease
FinlandCabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy
FinlandEfficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial
FinlandZongertinib for Cancer in Patients Eligible for Early Access Treatment
FinlandA study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.
FinlandStudy on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
FinlandStudy on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy
FinlandStudy on Betamethasone Sodium Phosphate to Prevent Asthma in Children with First-time Rhinovirus-induced Wheezing
FinlandFinlandStudy of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
FinlandStudy on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination
FinlandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
